全球多汗症治療市場2022-2028：按規模,份額,增長分析和預測治療（肉毒桿菌毒性A,離子電滲療法）,類型（原發性局灶性/繼發性全身性多汗症）,用戶（醫院,門診）

Global Hyperhidrosis Treatment Market Size, Share, Growth Analysis, By Treatment(Botulinum toxic A, lontophoresis), By Type(Primary focal, secondary generalized), By End User(Hospitals, ambulatory) - Industry Forecast 2022-2028

出版日期: 2022年10月03日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球多汗症治療市場規模預計將從 2021 年的 12 億美元增長到 2028 年的 20 億美元，預測期內復合年增長率為 6.2%。

繼發性多汗症發病率上升和進入者增加研發投資是推動市場增長的主要原因。

在本報告中，我們調查了全球多汗症治療市場，提供了市場概況，分析了市場的各種影響因素，技術和創新趨勢，市場規模的轉變和預測，總結了細分，競爭格局，主要公司簡介等

內容

執行摘要

母市場分析

市場概覽
市場規模
市場動態
司機
機會
約束因素
任務
主要市場洞察
技術分析
價格分析
供應鏈分析
價值鏈分析
市場生態系統
知識產權分析
貿易分析
啟動分析
原材料分析
創新矩陣
管道產品分析
宏觀經濟指標
主要投資分析
關鍵成功因素
競爭程度
市場動態和前景
市場動態
司機
機會
約束因素
任務
監管狀況
波特的分析
Skyquest 對未來顛覆的特別洞察
全球多汗症治療市場，按治療分類
市場概覽
A 型肉毒毒素
離子導入
手術治療
局部治療
汗腺的非手術微波能量破壞
其他

全球多汗症治療市場：按類型分類

市場概覽
原發性局灶性多汗症
繼發性全身性多汗症
全球多汗症治療市場：按最終用戶分類
市場概覽
醫院
門診
手術中心
其他
全球多汗症治療市場規模：按地區
市場概覽
北美
歐洲
亞太地區
拉丁美洲
中東和非洲
競爭格局
五家主要公司的比較
主要公司的市場定位
各大公司的招聘策略
關鍵成功策略
最近的市場活動
主要公司的市場份額
主要公司簡介
Allergan PLC
Brickell Biotech Inc.
Cynosure
Dermadry Laboratories lnc.
Dermira Inc.
GlaxoSmithKline PLC
Miramar Labs, Inc.
Sesderma
Ulthera Inc.

簡介目錄

Product Code: SQSG35J2014

Global hyperhidrosis treatment market was valued at USD 1.2 billion in 2021 and is expected to reach USD 2 billion by 2028. The market is anticipated to grow at a CAGR of 6.2% during the forecast period (2022-2028).

The first line of defence in the battle against hyperhidrosis is antiperspirants and topical drugs. Hyperhidrosis, however, has no known treatment at this time. In recent years, there has been a lot of activity in the development of new products and technology. Businesses have invested in this industry as a result of the public's growing awareness of potential therapies and patients' need for cutting-edge techniques.

The rising incidence of secondary hyperhidrosis diseases and market participants increasing their R&D investment are the main reasons fueling the market expansion for hyperhidrosis therapeutics. According to a study by Jared Brackenrich that was published in the National Library of Medicine in October 2021, this ailment is thought to occur quite frequently in the United States, with an estimated 3% incidence. Hyperhidrosis may impair social, psychological, emotional, and vocational functioning. Thus, it is predicted that the increasing prevalence of hyperhidrosis will increase the need for treatment and, as a result, accelerate market expansion.

A possible therapy pipeline for the ailment could have an effect on market growth in addition to favourable reimbursement policies, higher rates of anxiety and depression, and increased public awareness of hyperhidrosis. For instance, Brickell Biotech Inc. released encouraging topline findings from the Phase 3 pivotal Cardigan I and Cardigan II investigations in October 2021. These studies assessed the effectiveness of 15% sofpironium bromide gel applied topically once daily in patients with primary axillary hyperhidrosis.

Top-down and bottom-up approaches were used to estimate and validate the size of Asia Pacific Hyperhidrosis treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report

The market is divided into segments based on end user, area, kind of hyperhidrosis, and type of treatment. The market is segmented by type of treatment, including non-surgical microwave energy destruction of sweat glands, lontophoresis, surgical treatment, tropical treatment, and botulinum toxic A. There are two types of hyperhidrosis: primary focused and secondary widespread. It is separated into hospitals, ambulatory, surgical centres, and other facilities according on the end user (dermatology clinics & cosmetic centers). It is separated into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa based on region.

Driver

The effects of hyperhidrosis therapy based on radiofrequency microneedling on patients with the ailment are being studied by medical professionals. Stakeholders are attempting to discover whether fractional microneedle radiofrequency treatment offers long-term benefits, particularly for patients with primary axillary hyperhidrosis. These studies' analysis of the hyperhidrosis disease severity scale (HDSS) revealed that patients' conditions dramatically improved after taking medication.

Another hyperhidrosis treatment that is gaining popularity among patients is tap water iontophoresis, which involves transporting an ionised material through the skin using a direct electric current. In numerous treatment trials, patients with plantar and palmar hyperhidrosis demonstrated significant improvements. Patients are able to live better lifestyles and perspire significantly less as a result of these positive effects.

The most recent market-related R&D projects are gaining popularity on a global basis. For instance, Brickell Biotech Inc. released upbeat topline results from the Phase 3 pivotal Cardigan I and II studies, which examined the efficacy of 15% sofpironium bromide gel applied topically once daily in patients with primary axillary hyperhidrosis. This quickens market growth.

Restraints

Particularly botulinum toxin injections have a lot of drawbacks, such as its transient efficacy in people who grow less tolerant to the dosage as they become accustomed to it. Another issue harming the market for hyperhidrosis treatments is the financial load and psychological distress that patients endure as a result of many medical insurance companies not covering hyperhidrosis treatment.

Market Trends

OnabotulinumtoxinA can be used to treat excessive sweating in the armpits, hands, feet, head, face, and other relatively small body areas, according to an article that was published in the International Hyperhidrosis Society in October 2020. (such under the breasts). When used to treat excessive sweating beneath the arms, Botox has been shown to reduce sweating by 82-87%. The effects of treatment often begin to apparent two to four days after the procedure and reach their peak two weeks later. Despite typically lasting 4 to 12 months, dryness can continue up to 14 months, according to some research.

Several studies have shown how effective it is at reducing anxiety. A study from 2021 that was published in the journal Scientific Reports found that persons who had Botox injections at four different locations experienced significantly less anxiety than those who received other treatments for the same conditions. In Botox patients, anxiety was seen to be reduced by 22-72%.